# Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.

> **NCT00854867** · PHASE1 · COMPLETED · sponsor: **Mundipharma Research Limited** · enrollment: 18 (actual)

## Conditions studied

- Solid Tumour Neoplastic Meningitis
- Brain Metastases

## Interventions

- **DRUG:** Whole Brain Radio Therapy (WBRT) with sequential Depocyte
- **DRUG:** Whole brain radiotherapy (WBRT) with concomitant Depocyte

## Key facts

- **NCT ID:** NCT00854867
- **Lead sponsor:** Mundipharma Research Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00854867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00854867, "Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00854867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*